A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Eric Snoeck (1) , Pascal Chanu (2) , Marc Lavielle (3) , Philippe Jacqmin (1) , Niclas Jonsson (1) , Karin Jorga (2) , Timothy Goggin (2) , Joseph Grippo (2) , Shasha Jumbe (2) , Nicolas Frey (2)

1 Exprimo
2 F. Hoffmann-La Roche [Basel]
3 POPIX - Modélisation en pharmacologie de population

We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response (SVR)--the primary clinical end point of hepatitis C treatment, defined as an undetectable viral load at 24 weeks after completion of treatment)--in patients with chronic hepatitis C (CHC) who have received treatment with peginterferon α-2a ± ribavirin. The new attributes of our hepatitis C viral kinetic model are (i) the implementation of a cure/viral eradication boundary, (ii) employment of all hepatitis C virus (HCV) RNA measurements, including those below the lower limit of quantification (LLOQ), and (iii) implementation of a population modeling approach. The model demonstrated excellent positive (99.3%) and negative (97.1%) predictive values for SVR as well as high sensitivity (96.6%) and specificity (99.4%). The proposed viral kinetic model provides a framework for mechanistic exploration of treatment outcome and permits evaluation of alternative CHC treatment options with the ultimate aim of developing and testing hypotheses for personalizing treatments in this disease.

Domaines: Pharmacologie

Eric Snoeck, Pascal Chanu, Marc Lavielle, Philippe Jacqmin, Niclas Jonsson, et al.. A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure. Clinical Pharmacology and Therapeutics, 2010, 87 (6), pp.706-713. ⟨hal-00637434⟩